Analyst Price Targets — ADXN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 28, 2024 6:49 am | Raghuram Selvaraju | H.C. Wainwright | $30.00 | $10.52 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Addex Therapeutics (ADXN) |
Latest News for ADXN
Addex Therapeutics Ltd (ADXN) Q1 2026 Earnings Call Transcript
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 25, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its Q1 2026 financial results and provided a corporate update.
Geneva, Switzerland, June 22, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will report its First Quarter 2026 Financial Results on June 25, 2026. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business…
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 5, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that its 2026 Annual General Meeting will take place on Monday June 29, 2026 at 11:00 am CEST at the Campus Biotech, Chemin des…
Addex Therapeutics Ltd (ADXN) Q4 2025 Earnings Call Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ADXN.
U.S. House Trading
No House trades found for ADXN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.